The Gamma variant is NOT new, it's just been known by a more common name (P.1 aka Brazilian variant)
I am seeing so much confusion lately over all the variants.Hopefully this post clears a lot of this up.
Delta is the first variant that is NOW almost exclusively identified by the Greek letter nomenclature. Delta is the Indian variant, but the media is trying to take away geographical stigma.
Lambda (the Peruvian variant and newest Greek letter-denominated one as well, but Lambda is far less discussed atm) was the next that has been getting this treatment.
Now it is Gamma's turn (as Gamma is now starting to finally rapidly spread and gain footholds elsewhere).
This re-naming has lead to older variants now being identified by their Greek letter names as well and causing mass confusion.
There are currently 8 Greek letter named variants still listed (11 total Greek letters used, but 3 variants, Epsilon, Zeta, and Theta, have fallen off the lowest category listed, VOI).
Variants get the Greek letter name once they become a VOI (variant of interest)
There are currently 4 VOI¨s and then 4 VOC's (variants of concern, the next step up)
There is one final, highest rating. (VOHC) Variant of High Consequence. None have reached this level so far.
https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html
here is a chart for the current VOI and VOC's
Lambda is the newest, from Peru, the one I have been most worried about after Delta
https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/
Peru is getting crushed by Lambda, by far the highest death rate in the world atm.
https://www.worldometers.info/coronavirus/
I have always used the Pango names, not the Greek letters, BUT Delta has changed it for me.
Now I use both if not talking about Delta until people start to catch on (and hopefully me using both aids in that).
The Pango lineage nomenclature is being used by researchers and public health agencies worldwide to track the transmission and spread of SARS-CoV-2.
Perfect example is the one I started this OP with: P.1 aka Brazilian variant aka Gamma. P.1 is the Pango lineage name.
Beta (B.1.351 aka the South African variant)
Gamma (P.1 aka the Brazilian variant)
Delta (B.1.617.2 aka the Indian variant)
Lambda (C.37 aka the Peruvian variant)
here is the Greek alphabet
Again, you you will notice that we have used 11 Greek letters, but only 8 are in the VOI/VOC charts
that is because the Epsilon, Zeta, and Theta variants have fallen off the lowest level (VOI aka Variant of Interest)
= new reply since forum marked as read
so the were double infections.
The good news (to a point, as it is not available on a large scale yet) is that the Moderna mRNA-1273.351 variant-tweaked vax my wife and I are in a trial study for here in Sweden since April has shown huge (95-96%+) efficacy against both the Beta (B.!.351 the South African variant it was designed to crush) AND against Gamma (P.17Brazilan variant).
The original Moderna mRNA-1273 (the one that so many tens of millions gave been given) vax was already more effective against Delta (only a 2.1 fold reduction in antibody titers) than any of the other variants, so the tweaked vax is likely at least 90% or more in terms of efficacy against Delta.
After our blood draw last week, the doctors said that against lab-grown Delta strains, some cohorts are showing 93-94% efficacy (that is brand new info that I was given Friday, in the late afternoon via a follow up phone call from one of our study doctors).
They said they should have 'in-the-wild' variant data sets when we do our next blood draw (in regards to the the mRNA-1273.351 vax versus Delta variant).
here is screenshot from another thread I was in
https://www.democraticunderground.com/100215651719#post3
if you want a deep dive on that, here you go (remember this study below is the for the original Moderna mRNA-1273 vax, not the variant tweaked mRNA-1273.351 vax.)
Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants
https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1.full
ABSTRACT
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants has led to growing concerns over increased transmissibility and the ability of some variants to partially escape immunity. Sera from participants immunized on a prime-boost schedule with the mRNA-1273 COVID-19 vaccine were tested for neutralizing activity against several SARS-CoV-2 variants, including variants of concern (VOCs) and variants of interest (VOIs), compared to neutralization of the wild-type SARS-CoV-2 virus (designated as D614G). Results showed minimal effects on neutralization titers against the B.1.1.7 (Alpha) variant (1.2-fold reduction compared with D614G); other VOCs such as B.1.351 (Beta, including B.1.351-v1, B.1.351-v2, and B.1.351-v3), B.1.617.2 (Delta), and P.1 (Gamma) showed decreased neutralization titers ranging from 2.1-fold to 8.4-fold reductions compared with D614G, although all remained susceptible to mRNA-1273–elicited serum neutralization.
INTRODUCTION
As the coronavirus disease 2019 (COVID-19) pandemic continues to escalate in various parts of the world, several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of interest (VOIs) and variants of concern (VOCs) have emerged, including in the United States (B.1.526; Iota), United Kingdom (B.1.1.7; Alpha), Brazil (P.1; Gamma), India (B.1.617.1, Kappa; B.1617.2, Delta), South Africa (B.1.351; Beta), Uganda (A.23.1), Nigeria (B.1.525; Eta), and Angola (A.VOI.V2).1 There is growing concern over these variants based on increased transmissibility and the ability of some variants to partially escape both natural and vaccine-induced immunity. Notably, the B.1.617.2 lineage was recently classified as a VOC by the World Health Organization due to evidence of an increased rate of transmission, reduced effectiveness of monoclonal antibody treatment, and reduced susceptibility to neutralizing antibodies.1
We previously reported that mRNA-1273, a lipid nanoparticle encapsulated mRNA-based vaccine encoding the spike glycoprotein of the SARS-CoV-2 Wuhan-Hu-1 isolate, induced high neutralizing antibody titers in phase 1 trial participants2 and was highly effective in preventing symptomatic and severe COVID-19.3,4 Some VOCs or VOIs, including B.1.351 and P.1, reduced neutralizing antibody levels using a pseudovirus-based model.5 Importantly, however, all variants remained susceptible to mRNA-1273 vaccine–elicited serum neutralization.5 Here we provide an update on the neutralization activity of vaccine sera against several newly-emerged variants, including the Delta variant B.1.617.2.
now this is from TASS, so take it with a grain of salt, lol
WHO refuses to call AT.1 detected in Russian Federation ‘Russian variant’ of coronavirus
The organization has been tracking various strains since the beginning of the COVID-19 outbreak in January 2020
https://tass.com/society/1312169
GENEVA, July 9. /TASS/. The World Health Organization (WHO) believes that the AT.1 variant of the coronavirus detected in Russia that has been put on the monitoring list should not be called the "Russian variant". No country should be "stigmatized" for detecting and reporting variants, press service of the Geneva-headquartered organization told TASS.
"WHO is tracking a variant designated as an "Alert for Further Monitoring" that was first detected in Russia [Pango lineage AT.1]. However, we wouldn’t call it the "Russian variant". No country should be stigmatized for detecting and reporting variants," press service of the organization told TASS in reply to request letter about AT.1. Starting May 31, coronavirus variants of concern (VOC) and variants of interest (VOI) have been named with Greek letters, WHO noted.
AT.1 has not been given such a name, though it has been put on a separate monitoring list together with other 14 strains. It was detected in Russia in January 2021, whereas the World Health Organization put it on its monitoring list on June 9. Apart from AT.1, the list includes strains registered at different times in Brazil, Britain, Indonesia, the US, the Philippines, and other states.
WHO has been tracking variants since the beginning of the COVID-19 outbreak in January 2020, the organization noted. "With the emergence of new variants of concern, we are stepping up these efforts so that we can set up systems to quickly identify and study emerging variants. One of the reasons for why variants might emerge are the ‘selection pressures’ brought about by widespread transmission of the virus. We are emphasizing the importance of limiting transmission in our communications with countries and the public to limit the emergence of variants of concerns," press service said.
snip
https://cov-lineages.org/lineage.html?lineage=AT.1
https://outbreak.info/situation-reports?pango=AT.1
https://www.ecdc.europa.eu/en/covid-19/variants-concern
Ty! 
I'm wondering what chances are for fully vaxed who have only asymptomatic or mild cases ending up with long haul.
I really appreciate you asking doc! That was very kind of you! 
Let us all hope no VOHC's (Variant of High Consequence) pop up along the way or we are indeed well and truly fucked at that point.
And thanks for saving it to your journal so I can find it later!
❤
